US › Healthcare

Boundless Bio, Inc. Common Stock (BOLD)

US · Healthcare · Biotechnology

$2.71+5.25%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-13.6M
Profit YoY
+14.0%
EPS
$-0.60
EPS estimate
$-0.51

EPS came in at -0.60 against a street estimate of -0.51 — a miss of 17.6%.

Key statistics

Market cap
$56.2M
Forward P/E
0.0
P/B
0.65
Book value
$3.85
EPS (TTM)
$-2.49
52-week high
$2.79
52-week low
$0.96
50-day MA
$2.03
200-day MA
$1.45
Beta
0.40

Analyst view

Analysts rate Boundless Bio, Inc. Common Stock a hold (1 buy, 2 hold, 0 sell out of 3) with an average price target of $4.00.

Shareholding

Insiders
11.35%
Institutions
61.09%

Largest institutional holders

FundStake
FMR Inc11.99%
Citadel Advisors Llc5.97%
Sectoral Asset Management Inc3.02%
Stonepine Capital Management Llc2.66%
Vanguard Capital Management, LLC2.66%
Wellington Management Company LLP2.47%
Renaissance Technologies Corp1.78%
Alyeska Investment Group, L.P.1.33%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Boundless Bio, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.